Wired News – Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors

Stock Monitor: Albireo Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Agios Pharma, Inc. (NASDAQ: AGIO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AGIO as the Company’s latest news hit the wire. On March 19, 2018, the Company announced that it has dosed first patient in a Phase-1, open-label, dose-escalation and expansion study investigating AG-270 in patients with solid tumors or lymphoma with deletion of the metabolic gene methylthioadenosine phosphorylase (MTAP). AG-270 is a first-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcare sector as the Company Agios Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ALBO

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Agios Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AGIO

AG-270 has the Potential to Benefit Patients Whose Cancer is Characterized by Loss of MTAP

Scott Biller, M.D., Chief Scientific Officer of Agios, mentioned that in addition to significant milestones for its late-stage portfolio this year, the Company is pleased to demonstrate the continued productivity of its research engine by advancing sixth internally discovered molecule into the clinic.

Scott added that as a first-in-class MAT2A inhibitor, AG-270 has the potential to benefit the large number of patients whose cancer is characterized by the loss of MTAP. Agios will conduct the early clinical work that will explore the pharmacology and clinical activity of MAT2A inhibition in tumors carrying this deletion. The estimated date for completion of the study is October 2020.

FDA Granted Clearance to IND for AG-270 Targeting MTAP-Deleted Tumors

In December 2017, the US Food and Drug Administration (FDA) completed their 30-day safety review of the investigational new drug (IND) application for AG-270 and granted IND clearance to proceed with the proposed Phase-1 dose-escalation trial in multiple tumor types carrying an MTAP deletion.

About AG-270 Phase-1 Study Design

The purpose of this Phase-1, multicenter, open label study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) in approximately 50 patients, when given daily by mouth to subjects with advanced solid tumors or lymphoma with homozygous deletion of MTAP. The first portion of this study is dose escalation, where cohorts of subjects will receive ascending oral doses of AG-270 to determine the MTD, the dose with maximum pharmacologic activity or a maximum feasible dose. In the dose expansion portion of the study, additional subjects will be treated at the MTD (or one of the described alternative doses) to further characterize that dose’s safety, tolerability, PK and PD, and to detect preliminary evidence of anti-tumor activity. The dose-expansion phase of the study will support the selection of a dose for future clinical studies.

Agios-Celgene Collaboration

AG-270 is part of a 2016 global research collaboration agreement with Celgene Corp. Celgene has the option to participate in a worldwide cost and profit share with Agios, under which the parties will share all development costs, subject to specified exceptions, and any profits on net sales and Agios will be eligible for up to $169 million in clinical and regulatory milestone payments for the program.

About Agios Pharmaceuticals, Inc.

Established in 2008, Agios Pharma is a biopharmaceutical company focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. The Company is headquartered in Cambridge, Massachusetts.

Stock Performance Snapshot

March 20, 2018 – At Tuesday’s closing bell, Agios Pharma’s stock rose 1.16%, ending the trading session at $82.70.

Volume traded for the day: 307.14 thousand shares.

Stock performance in the last month – up 6.44%; previous three-month period – up 58.67%; past twelve-month period – up 47.26%; and year-to-date – up 44.66%

After yesterday’s close, Agios Pharma’s market cap was at $4.78 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 493776